Ligand Pharmaceuticals Inc. Stock OTC Bulletin Board
Equities
US53220K1815
Pharmaceuticals
End-of-day quote
Other stock markets
|
||
- USD | - |
Financials (USD)
Sales 2024 * | 138M | Sales 2025 * | 157M | Capitalization | 1.42B |
---|---|---|---|---|---|
Net income 2024 * | 92M | Net income 2025 * | 50M | EV / Sales 2024 * | 10.3 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 9 x |
P/E ratio 2024 * |
15.8
x | P/E ratio 2025 * |
24.5
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.65% |
Latest transcript on Ligand Pharmaceuticals Inc.
Managers | Title | Age | Since |
---|---|---|---|
Todd Davis
CEO | Chief Executive Officer | 63 | 07-02-28 |
Octavio Espinoza
DFI | Director of Finance/CFO | 53 | 22-10-31 |
President | 49 | 15-08-05 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Kozarich
CHM | Chairman | 74 | 03-02-28 |
John LaMattina
BRD | Director/Board Member | 74 | 11-01-31 |
Stephen Sabba
BRD | Director/Board Member | 64 | 08-08-03 |
1st Jan change | Capi. | |
---|---|---|
+54.61% | 815B | |
+44.25% | 654B | |
-6.33% | 354B | |
+20.62% | 337B | |
+10.44% | 302B | |
+18.45% | 247B | |
+2.09% | 229B | |
+13.03% | 219B | |
+8.61% | 171B |